Genmab A/S announced updated results from the Phase 2 EPCORE NHL-6 trial, evaluating investigational epcoritamab monotherapy administered in an outpatient setting for adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated the feasibility of treating and monitoring patients in an outpatient setting following the first dose of epcoritamab.
The incidence and severity of adverse events, including cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS), were consistent with previous epcoritamab studies and primarily low grade. CRS events occurred in 30% of patients receiving the first full dose in the outpatient setting, with 10 patients managed in outpatient and 11 requiring inpatient care, all resolving with a median time of two days.
The study also reported an overall response rate (ORR) of 64.3% and a complete response (CR) rate of 47.6% in patients treated after only one prior line of systemic therapy, with a median follow-up of 5.8 months. This outpatient viability could provide broader access to this treatment option across various sites of care, including community settings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.